Early Aubagio use can delay clinically definite MS
This article was originally published in Scrip
Executive Summary
Early treatment with Sanofi/Genzyme’s Aubagio (teriflunomide) in patients who experience their first neurological symptoms suggestive of multiple sclerosis (MS) could prevent or delay further onset of the disease, topline data from the TOPIC study suggest.